Tonix Pharmaceuticals Holding Corp., a clinical-stage company that develops first-in-class medicines for common disorders of the central nervous system, including post-traumatic stress disorder, fibromyalgia and episodic tension-type headache, recently announced the presentation of new results of the BESTFIT study, a Phase 2b trial that examined the efficacy of TNX-102 SL in fibromyalgia. The presentation will take place on June 10-13 in Rome, Italy during the 16th Annual European Congress of Rheumatology, hosted by the European League Against Rheumatism (EULAR).
Tonix’s lead product candidate, TNX-102 SLAttribution(cyclobenzaprine HCl sublingual tablet), is designed to be a fundamental advance in sleep hygiene and pain management for patients suffering from fibromyalgia and post-traumatic stress disorder (PTSD). Product candidate TNX-201Attribution (®-isometheptene mucate) is in development for episodic tension-type headache, the most common form of headache.
The poster presentation titled “TNX-102 SL for Treatment of Fibromyalgia: Approaches to Pain Measurement,” will be presented on the 11th of June from 12:00 p.m. to 1:45 p.m. by R. Michael Gendreau, M.D., Ph.D., Principal, Gendreau Consulting.
The other presentation titled “TNX-102 SL for the Treatment of Fibromyalgia: Role of Nonrestorative Sleep on Pain Centralization,” will be presented on the 11th of June from 12:00 p.m. to 1:45 p.m by Seth Lederman, M.D., CEO, Tonix Pharmaceuticals.
The details of the presentations can be found at www.congress.eular.org.
TNX-102 SL is currently being evaluated in the Phase 3 AFFIRM study in fibromyalgia and in the Phase 2 AtEase study in post-traumatic stress disorder. A Phase 2 proof-of-concept study of TNX-201 for episodic tension-type headache will begin in the second quarter of 2015.